Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.09M Sell
81,002
-3,848
-5% -$268K 0.01% 1049
2025
Q4
$5.64M Buy
84,850
+40,654
+92% +$2.63M 0.01% 956
2025
Q3
$2.97M Sell
44,196
-764
-2% -$60.5K ﹤0.01% 1195
2025
Q2
$3.92M Buy
44,960
+8,082
+22% +$634K 0.01% 980
2025
Q1
$2.52M Buy
36,878
+7,149
+24% +$583K ﹤0.01% 1114
2024
Q4
$2.31M Buy
29,729
+442
+2% +$32.7K ﹤0.01% 1136
2024
Q3
$1.96M Sell
29,287
-61,496
-68% -$5.05M ﹤0.01% 1196
2024
Q2
$10.3M Buy
90,783
+6,531
+8% +$826K 0.02% 501
2024
Q1
$11.7M Buy
84,252
+45,439
+117% +$5.71M 0.02% 468
2023
Q4
$4.82M Buy
38,813
+4,295
+12% +$439K 0.01% 690
2023
Q3
$3.22M Buy
34,518
+2,186
+7% +$246K 0.01% 792
2023
Q2
$4.15M Buy
32,332
+966
+3% +$117K 0.01% 708
2023
Q1
$3.64M Buy
31,366
+1,406
+5% +$157K 0.01% 731
2022
Q4
$3.39M Buy
29,960
+2,441
+9% +$268K 0.01% 727
2022
Q3
$2.22M Buy
27,519
+7,432
+37% +$629K 0.01% 734
2022
Q2
$1.5M Buy
+20,087
New +$1.83M 0.01% 790
2019
Q3
Sell
-21,040
Closed -$788K 775
2019
Q2
$788K Buy
+21,040
New +$661K 0.01% 588

Other funds holding DXCM

Mariner's DXCM Position: Q1 2026 in Review

Mariner reduced its DexCom (DXCM) stake by 4.5% in Q1 2026, selling an estimated $268K and leaving 81,002 shares worth $5.09M. The position accounts for 0.01% of the portfolio, ranked #1049.

Mariner first reported a position in DXCM in Q2 2019 and has held it in 17 quarters since. The position peaked at $11.7M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Mariner held 81,002 shares of DexCom worth $5.09M as of Q1 2026.
  • Mariner sold 3,848 DexCom shares in Q1 2026, an estimated $268K.
  • DexCom made up 0.01% of Mariner's portfolio in Q1 2026, its #1049 holding.
  • Mariner first reported a position in DexCom in Q2 2019 and has held it in 17 quarters since.
  • Mariner's DexCom position peaked at $11.7M in Q1 2024.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.